Q4B Annex 10 R1 Step 4

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL
REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
ICH HARMONISED TRIPARTITE GUIDELINE
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL

TEXTS FOR USE IN THE ICH REGIONS ON
POLYACRYLAMIDE GEL ELECTROPHORESIS
GENERAL CHAPTER
Q4B ANNEX 10(R1)
Current Step 4 version

dated 27 September 2010
This Guideline has been developed by the appropriate ICH Expert Working Group
and has been subject to consultation by the regulatory parties, in accordance with the
ICH Process. At Step 4 of the Process the final draft is recommended for adoption to
the regulatory bodies of the European Union, Japan and USA.
Q4B Annex 10(R1)
Document History
Code History Date

Approval by the Steering Committee under Step 2 and
Q4B Annex 10 11 June 2009
release for public consultation.
Approval by the Steering Committee under Step 4 and

29 October
Q4B Annex 10 recommendation for adoption to the three ICH regulatory
2009
bodies.
Current Step 4 version

Q4B Annex Integration of the Health Canada Interchangeability 27 September
10(R1) Statement under Section 4.5 after approval by the Steering 2010
Committee.
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS
FOR USE IN THE ICH REGIONS
ON
POLYACRYLAMIDE GEL ELECTROPHORESIS GENERAL CHAPTER
ICH Harmonised Tripartite Guideline

Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting
on 29 October 2009, this guideline is recommended for
adoption to the three regulatory parties to ICH
(This annex was revised -R1- to include the Interchangeability Statement from
Health Canada on September 27, 2010)
TABLE OF CONTENTS
1. INTRODUCTION ........................................................................................................... 1
2. Q4B OUTCOME .............................................................................................................. 1
2.1 Analytical Procedures ........................................................................................... 1
2.2 Acceptance Criteria ............................................................................................... 1
3. TIMING OF ANNEX IMPLEMENTATION .......................................................... 1
4. CONSIDERATIONS FOR IMPLEMENTATION ................................................ 1
4.1 General Consideration .......................................................................................... 1
4.2 FDA Consideration ................................................................................................ 1
4.3 EU Consideration .................................................................................................. 2
4.4 MHLW Consideration ........................................................................................... 2
4.5 Health Canada Consideration .............................................................................. 2
5. REFERENCES USED FOR THE Q4B EVALUATION ..................................... 2
i
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR
USE IN THE ICH REGIONS
ON
POLYACRYLAMIDE GEL ELECTROPHORESIS GENERAL CHAPTER
Q4B ANNEX 10(R1)
1. INTRODUCTION
This annex is the result of the Q4B process for the Polyacrylamide Gel Electrophoresis
General Chapter.
The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).
2. Q4B OUTCOME
2.1 Analytical Procedures

The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group
(EWG), recommends that the official pharmacopoeial texts, the Section in Ph.Eur. 2.2.31.
Electrophoresis entitled Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis
(SDS-PAGE), JP General Information 23. SDS-Polyacrylamide Gel Electrophoresis, and
USP <1056> Biotechnology-derived Articles – Polyacrylamide Gel Electrophoresis, can be
used as interchangeable in the ICH regions.
2.2 Acceptance Criteria

The texts evaluated did not contain acceptance criteria.
3. TIMING OF ANNEX IMPLEMENTATION
When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in
a region, it can be used in that region. Timing might differ for each region.
4. CONSIDERATIONS FOR IMPLEMENTATION
4.1 General Consideration

When sponsors or manufacturers change their existing methods to the implemented Q4B-
evaluated pharmacopoeial texts that are referenced in Section 2.1 of this annex, any change
notification, variation, and/or prior approval procedures should be handled in accordance
with established regional regulatory mechanisms pertaining to compendial changes.
4.2 FDA Consideration

Based on the recommendation above, and with reference to the conditions set forth in this
annex, the pharmacopoeial texts referenced in Section 2.1 of this annex can be considered
interchangeable. However, FDA might request that a company demonstrate that the chosen
1
Polyacrylamide Gel Electrophoresis General Chapter
method is acceptable and suitable for a specific material or product, irrespective of the
origin of the method.
4.3 EU Consideration
For the European Union, regulatory authorities can accept the reference in a marketing
authorisation application, renewal or variation application citing the use of the
corresponding text from another pharmacopoeia as referenced in Section 2.1, in accordance
with the conditions set out in this annex, as fulfilling the requirements for compliance with
the Ph. Eur. Chapter 2.2.31. on the basis of the declaration of interchangeability made
above.
4.4 MHLW Consideration

The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as
interchangeable in accordance with the conditions set out in this annex. Details of
implementation requirements will be provided in the notification by MHLW when this
annex is implemented.
4.5 Health Canada Consideration

In Canada, any of the pharmacopoeial texts cited in section 2.1 of this annex and used in
accordance with the conditions set out in this annex can be considered interchangeable.
5. REFERENCES USED FOR THE Q4B EVALUATION
5.1 The PDG Stage 5B sign-off document: Japanese Pharmacopoeial Forum, Volume 9,
number 1 (January 2000).
5.2 The pharmacopoeial references for Polyacrylamide Gel Electrophoresis General
Chapter for this annex are:
5.2.1 European Pharmacopoeia (Ph. Eur.): 6th Edition (official in January 2008),
Electrophoresis (reference 01/2008:20231);
5.2.2 Japanese Pharmacopoeia (JP): The JP General Information 23. SDS-

Polyacrylamide Gel Electrophoresis as it appears in the Japanese
Pharmacopoeia Fifteenth Edition (March 31, 2006, The Ministry of Health,
Labour and Welfare Ministerial Notification No. 285);
5.2.3 United States Pharmacopeia (USP): <1056> Biotechnology-derived Articles –

Polyacrylamide Gel Electrophoresis official in USP 32, May 1, 2009.

Q4B Annex 10 R1 Step 4

Uploaded by

Copyright:

Available Formats

Q4B Annex 10 R1 Step 4

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Q4B Annex 10 R1 Step 4

Uploaded by

Copyright:

Available Formats

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL

REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

ICH HARMONISED TRIPARTITE GUIDELINE

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL

Q4B ANNEX 10(R1)

Current Step 4 version

Code History Date

Approval by the Steering Committee under Step 4 and

Current Step 4 version

ICH Harmonised Tripartite Guideline

2.1 Analytical Procedures

2.2 Acceptance Criteria

3. TIMING OF ANNEX IMPLEMENTATION

4. CONSIDERATIONS FOR IMPLEMENTATION

4.1 General Consideration

4.2 FDA Consideration

4.4 MHLW Consideration

4.5 Health Canada Consideration

5. REFERENCES USED FOR THE Q4B EVALUATION

5.2.2 Japanese Pharmacopoeia (JP): The JP General Information 23. SDS-

5.2.3 United States Pharmacopeia (USP): <1056> Biotechnology-derived Articles –

You might also like

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.